LIANHUA (00980) announced that the net loss attributable to owners of the company for 2025 is approximately 200 million yuan, a year-on-year decrease of 44.18%.
Lianhua Supermarket (00980) announced its performance for the year 2025, with a turnover of approximately RMB 17.753 billion, a year-on-year decrease of approximately 9.9%. Among them, the revenue of large comprehensive supermarkets decreased by about 14.7%, hypermarkets decreased by about 5.9%, and convenience stores decreased by about 11.2%. The gross profit is approximately RMB 2.088 billion, a year-on-year decrease of about 12.0%, with a gross profit margin of approximately 11.76%, a year-on-year decrease of about 0.27 percentage points. The net loss attributable to the company's shareholders for the year is approximately RMB 0.2 billion, a year-on-year decrease of 44.18%; the basic loss per share is approximately RMB 0.14.
LIANHUA (00980) announced its performance for the year 2025, with a turnover of approximately RMB 17.753 billion, a decrease of about 9.9% year-on-year. Among them, the turnover of large comprehensive supermarkets decreased by about 14.7%, the turnover of superstores decreased by about 5.9%, and the turnover of convenience stores decreased by about 11.2%. The gross profit is approximately RMB 2.088 billion, a decrease of about 12.0% year-on-year, with a gross profit margin of approximately 11.76%, a decrease of about 0.27 percentage points year-on-year. The net loss attributable to the company's shareholders for this year is approximately RMB 200 million, a decrease of 44.18% year-on-year; the basic loss per share is approximately RMB 0.14 yuan.
The announcement stated that the decrease in turnover was mainly affected by the continued impact of changes in consumer shopping habits and the diversification of consumption channels leading to the diversion of customer flow. At the same time, the group's overall strategic planning has been adjusted to focus on the core markets of Shanghai and Zhejiang, selling off some stakes of subsidiary companies, reducing the scale of sales with no profit, resulting in a decrease in overall sales scale.
Related Articles

DATANG POWER(00991) completes issuance of 2 billion yuan of commercial paper

SIHUAN PHARM (00460) signs a strategic partnership with Biocytogen Pharmaceuticals (02315) to accelerate research and development in various areas including weight loss using an AI-driven fully human antibody development platform.

PICC P&C (02328) will distribute a final dividend of 0.44 yuan per share on August 28th.
DATANG POWER(00991) completes issuance of 2 billion yuan of commercial paper

SIHUAN PHARM (00460) signs a strategic partnership with Biocytogen Pharmaceuticals (02315) to accelerate research and development in various areas including weight loss using an AI-driven fully human antibody development platform.

PICC P&C (02328) will distribute a final dividend of 0.44 yuan per share on August 28th.






